Dermatological Manifestations of Pegylated Interferon Alfa-2a and Ribavirin Combination Therapy in Chronic HCV Patients

    Mohamed Hamed Khater, Fathia M. Khattab, Mohamed Refaey
    Studysummary In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →